Overview

Treatment of the Anemia of Myelodysplastic Syndromes by the Association of Epoetin Beta and All Trans Retinoic Acid

Status:
Unknown status

Trial end date:
2005-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is - To evaluate the efficacy of association of Erythropoetin (Neorecormon) and ATRA in patients with low risk myelodysplastic syndromes - To evaluate the tolerance of this treatment

Phase:

Phase 2

Details

Lead Sponsor:

Groupe Francophone des Myelodysplasies

Treatments:

Epoetin Alfa
Tretinoin